Teva Says FDA Accepts BLA For Fremanezumab - Quick Facts

Teva Pharmaceutical Industries Ltd. (TEVA) said that the U.S. Food and Drug Administration has accepted for review the company's Biologics License Application or BLA for fremanezumab, an anti-calcitonin gene-related peptide or anti-CGRP monoclonal antibody for the preventive treatment of migraine.

from RTT - Biotech http://ift.tt/2zjF5kg
via IFTTT